I. E. Kuppens

发表

Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours

J. Schellens, J. Beijnen, G. Sanderink, 2005, Cancer Chemotherapy and Pharmacology.

Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.

J. Schellens, J. Beijnen, I. E. Kuppens, 2004, Clinical colorectal cancer.

Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors

J. Schellens, J. Beijnen, J. Bonneterre, 2006, Clinical Cancer Research.

A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients

J. Schellens, J. Beijnen, E. Voest, 2007, Clinical Cancer Research.

Capecitabine induces severe angina-like chest pain.

J. Schellens, J. Beijnen, H. Boot, 2004, Annals of internal medicine.

Current state of the art of new tubulin inhibitors in the clinic.

I. E. Kuppens, 2006, Current clinical pharmacology.

Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2005, Biomedical chromatography : BMC.

Modulation of Oral Drug Bioavailability: From Preclinical Mechanism to Therapeutic Application

J. Schellens, J. Beijnen, P. Breedveld, 2005, Cancer investigation.

Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors

J. Schellens, J. Beijnen, E. Voest, 2007, Investigational New Drugs.

Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093)

J. Schellens, H. Rosing, J. Beijnen, 2004, Cancer Chemotherapy and Pharmacology.